Percheron Therapeutics Limited (ASX:PER)
Australia · Delayed Price · Currency is AUD 0.0040
0.00 (0.00%)
Sep 10, 2026, 8:23 AM AEST
Percheron Therapeutics Company Description
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia.
Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA).
The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023.
Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Percheron Therapeutics Limited
| Country | Australia |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Michael Baker |
Contact Details
Address: Collins Place Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9827 8999 |
| Website | percherontx.com |
Stock Details
| Ticker Symbol | PER |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ANP4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBBS | Chief Executive Officer, MD and Director |
| Deborah Ambrosini B.Com., F.C.A. | Company Secretary and Chief Financial Officer |
| Valentina Dubljevic BSc, GAICD, MBB | Chief Technology Officer |
| Dr. Eugene P. Kennedy F.A.C.S., M.D. | Chief Medical Officer |